Alnylam is a leader in the emerging field of RNA interference-based therapeutics development, and the first to land a deal with a Big Pharma (Merck). Its focus is to discover and develop therapies for a range of diseases including viral infection, oncology, and autoimmune diseases.
790 Memorial Drive
Cambridge, MA 02139
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.
A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.
